CH BIOTECH SER (08037) has announced that all conditions precedent under the subscription agreement have been satisfied. The issuance of convertible bonds with a total principal amount of $35 million to the subscriber was completed on February 20, 2026, in accordance with the terms and conditions of the subscription agreement.

Prior to this issuance, there remained outstanding 2024 convertible bonds with a principal amount of $6 million. These bonds were convertible into a total of 39.25 million shares at a conversion price of HK$1.20 per share.

Following the completion of the new convertible bond issuance on February 20, 2026, as stipulated by the terms of the 2024 convertible bonds, the conversion price for the 2024 bonds has been adjusted from HK$1.20 per share to HK$1.11 per share. Consequently, the maximum number of shares to be issued by the company upon the full conversion of the 2024 convertible bonds is now 42.4324 million shares. This adjustment is effective from February 20, 2026, the completion date of the new bond issuance.

All other terms of the 2024 convertible bonds remain unchanged aside from the aforementioned adjustment.